Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02747329
Other study ID # PIONEER-II OCT
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 15, 2016
Est. completion date March 3, 2021

Study information

Verified date October 2021
Source Sino Medical Sciences Technology Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is a comparative evaluation of BuMA Supreme™ stent and of Xience V/Prime stent in terms of the extent of neointima formation at 1 or 2 months after implanting in relatively high bleeding risk patients with coronary artery disease using OCT.


Description:

This is a prospective, multicenter, randomized, non-inferiority study, which will enroll a total of 80 subjects from approximately 8 centers. All subjects will be firstly randomly assigned to 1st month OCT (40 pts) or 2nd month OCT group(40 pts). Then both two groups will be randomly assigned to undergoing implantation of BuMA Supreme™ stent (20 pts) or Xience V/Prime stent (20 pts). If non-inferiority was met, superiority test will be planned. All of the patients be followed up to 2 years. The follow-up visits will be conducted at 1 or 2 months (including QCA/OCT investigation), 3 months, 6 months, 1 and 2 years post percutaneous coronary intervention(PCI),in order to observe the Primary Endpoint and Secondary Endpoints.


Recruitment information / eligibility

Status Completed
Enrollment 82
Est. completion date March 3, 2021
Est. primary completion date May 11, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 85 Years
Eligibility Inclusion Criteria: 1. 18 to 85 years. 2. Evidence of myocardial ischemia without raised troponin (e.g. stable or unstable angina, silent ischemia demonstrated by positive territorial functional study). 3. Any one or more situation listed below can be considered the patient at high bleeding risk by the doctor: - Adjunctive oral anticoagulation treatment planned to continue after PCI; - Baseline Hb =11 g/dl (or anemia requiring TF during the prior 4 weeks); - Any prior intra-cerebral bleed at any time; - Any stroke during the past year; - Hospital admission for bleeding during the prior 12 months; - Non-skin cancer diagnosed or treated = 3 years; - Planned daily NSAID (other than aspirin) or steroids for = 30 days after PCI; - Planned major surgery (within 1 year); - Renal failure (calculated creatinine clearance = 40 ml/min); - Thrombocytopenia (= 100,000/mm3); - Severe chronic liver disease (variceal hemorrhage, ascites, hepatic encephalopathy or jaundice); - Expected non-compliance to prolonged DAPT for other medical (nonfinancial)reasons ; - NSAID, Non-steroidal anti-inflammatory drug; TF, blood transfusion. 4. The patient has a planned intervention of up to two de novo lesions, in different epicardial vessels. 5. Lesion(s) must have a visually estimated diameter stenosis of =70% and <100%. 6. Reference Vessel Diameter (RVD) must be between 2.5- 4.0mm, and the vessel length must be no more than 40 mm. 7. Written informed consent. 8. The patient and the patient's physician agree to the follow-up visits including angiographic follow-up and OCT controls at 1 or 2 month. Exclusion Criteria: 1. Evidence of ongoing acute myocardial infarction in ECG prior to procedure. 2. Left ventricular ejection fraction (LVEF) <30%. 3. The patient is a recipient of a heart transplant. 4. Known hypersensitivity or contraindication to aspirin, both heparin and bivalirudin, antiplatelet medication specified for use in the study (clopidogrel and ticlopidine), sirolimus or stainless steel, cobalt metal or sensitivity to contrast media, which cannot be adequately pre-medicated. 5. Other medical illness (e.g. skin cancer diagnosed or treated > 3 years, neurological deficiency) or known history of substance abuse (alcohol etc.) as per physician judgment that may cause non-compliance with the protocol or confound the data interpretation or is associated with a limited life expectancy. 6. Pregnant or breastfeeding woman or woman in fertile period not taking adequate contraceptives 7. Chronic total occlusion(TIMI 0), left main lesion, intervention-required three-vessel lesions, branch vessel diameter = 2.5mm and bypass lesion 8. Patients expected not to comply with 1 month DAPT; 9. Compliance with long-term single anti-platelet therapy unlikely; 10. Active bleeding at the time of inclusion; 11. Patients requiring a planned staged PCI procedure more than one week after theindex procedure; 12. Procedure planned to require non-study stents, or stand alone POBA or stand-alone atherectomy; 13. Reference vessel diameter <2.25 - >4.0mm, vessel length >40mm; 14. Cardiogenic shock; 15. Participation in another clinical trial (12 months after index procedure). 16. Those who is not suitable to attend this trial after the evaluation by the doctor. OCT exclusion criteria - Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in suboptimal imaging or excessive risk of complication from placement of an OCT catheter - Total occlusion or thrombolysis in myocardial infarction(TIMI) flow 0, prior to wire crossing.

Study Design


Intervention

Device:
BuMA Supreme™ stent

Xience V/Prime stent


Locations

Country Name City State
China The PLA General Hospital BeiJing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Sino Medical Sciences Technology Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The percentage of the struts' neointimal coverage (%) at 1 or 2 months follow-up by OCT assessment. 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group 1 or 2 months
Secondary Neointimal hyperplasia area/volume 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group 1 or 2 months
Secondary Mean/Minimal Stent diameter/area/volume 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group 1 or 2 months
Secondary Mean/Minimal Lumen diameter/area/volume 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group 1 or 2 months
Secondary Mean/maximal thickness of the struts coverage 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group 1 or 2 months
Secondary Incomplete strut apposition 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group 1 or 2 months
Secondary Minimal Lumen Diameter(MLD) and Diameter stenosis percentage(%DS) post procedure and at 3 months 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group 1 or 2 months
Secondary Late Lumen Loss 1 month OCT assessment is suitable for 1st month OCT group and 2 months OCT assessment is suitable for 2nd month OCT group 1 or 2 month
Secondary Binary Restenosis (DS =50%) All measurements will be made of the in-stent, in-segment, proximal and distal stent margins. 1 or 2 months
Secondary Acute success rate It includes the device success,lesion success and procedural success. up to 7 days
Secondary Device-oriented Composite Endpoints and its individual components Device-oriented Composite Endpoint (DoCE) is defined as cardiac death, Myocardial Infarction(MI) not clearly attributable to a non-intervention vessel, and clinically-indicated target lesion revascularization. 1 or 2, 3, 6 months, 1 year, 2 years
Secondary Stent thrombosis according to the ARC definitions Definite and probable stent thrombosis during acute, subacute, later and very late phase. 1 or 2, 3, 6 months, 1 year, 2 years
Secondary bleeding events 1 or 2, 3, 6 months, 1 year, 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A